EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link: https://ebookbell.com/faq

We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.

For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Public Engagement And Clinical Trials New Models And Disruptive Technologies 1st Edition Victoria Weisfeld

Name: Public Engagement And Clinical Trials New Models And Disruptive Technologies 1st Edition Victoria Weisfeld
SKU: BELL-2482038
Price: 31.00 USD
Availability: InStock
Rating: 5 (30 reviews)

SKU: BELL-2482038

$ 31.00 ~~$ 45.00~~ (-31%)

5.0

30 reviews

Public Engagement And Clinical Trials New Models And Disruptive Technologies 1st Edition Victoria Weisfeld instant download after payment.

Publisher: The National Academies Press

File Extension: PDF

File size: 6.11 MB

Pages: 117

Author: Victoria Weisfeld, Rebecca A. English, Anne B. Claiborne

ISBN: 9780309219297, 0309219299

Language: English

Year: 2011

Edition: 1

Product desciption

Public Engagement And Clinical Trials New Models And Disruptive Technologies 1st Edition Victoria Weisfeld by Victoria Weisfeld, Rebecca A. English, Anne B. Claiborne 9780309219297, 0309219299 instant download after payment.

Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a workshop June 27-28, 2011, to engage stakeholders and experts in a discussion about possible solutions to improve public engagement in clinical trials.